Capricor Therapeutics (CAPR) Interest & Investment Income (2010 - 2026)
Capricor Therapeutics (CAPR) recorded quarterly Interest & Investment Income of $2.9 million in Q1 2026, up 43.7% quarter-over-quarter from $2.0 million in Q4 2025, and up 298.13% on a YoY basis from $729542.0 in Q1 2025.
Capricor Therapeutics (CAPR) Interest & Investment Income (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 298.13% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $8.4 million (up 242.69% YoY), while the FY2025 annual figure was $6.3 million, up 184.05% from the prior year.
- Interest & Investment Income was $2.9 million for Q1 2026 at Capricor Therapeutics, up from $2.0 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2.9 million in Q1 2026 to a low of $13440.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $800902.3 across 5 years, with a median of $471829.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income surged 2998.53% in 2023, then fell 5.47% in 2024.
- A 5-year view of Interest & Investment Income shows it stood at $379699.0 in 2022, then grew by 19.09% to $452199.0 in 2023, then soared by 51.83% to $686572.0 in 2024, then soared by 194.39% to $2.0 million in 2025, then soared by 43.7% to $2.9 million in 2026.
- The last three Interest & Investment Income figures came in at $2.9 million (Q1 2026), $2.0 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 597,319.59 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -14.79 Mn |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 2.02 Mn |
| Sep 30, 2025 | 1.71 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 729,542.00 |
| Dec 31, 2024 | 686,572.00 |
| Sep 30, 2024 | 453,152.00 |
| Jun 30, 2024 | 591,437.00 |
| Mar 31, 2024 | 471,829.00 |
| Dec 31, 2023 | 452,199.00 |
| Sep 30, 2023 | 479,380.00 |
| Jun 30, 2023 | 380,680.00 |
| Mar 31, 2023 | 416,442.00 |
| Dec 31, 2022 | 379,699.00 |
| Sep 30, 2022 | 106,635.00 |
| Jun 30, 2022 | 21,761.00 |
| Mar 31, 2022 | 13,440.00 |
| Dec 31, 2021 | 15,984.00 |
| Sep 30, 2021 | 15,570.00 |
| Jun 30, 2021 | 16,741.00 |